A blueprint for the future of pharma medical affairs is being discussed, with various companies and organizations announcing expansions and launches of new business units, including medical affairs, consultancy, and data/tech units. There is also a focus on reimagining data governance, patient impact, and the use of artificial intelligence in the pharmaceutical industry. The scope of the blueprint appears to be broad, with some outlets discussing global health security and regional healthcare transformation, while others highlight specific treatments and technologies.